STRO - Sutro Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.73
+0.13 (+1.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.60
Open10.60
Bid10.66 x 1400
Ask20.00 x 1200
Day's Range10.39 - 11.00
52 Week Range7.69 - 15.90
Volume76,588
Avg. Volume56,447
Market Cap246.016M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.34
Earnings DateNov 11, 2019 - Nov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.50
Trade prices are not sourced from all markets
  • PR Newswire

    Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 4, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, Sept. 10, 2019, at 11:40 AM EDT, in New York City. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • Targeting flesh-eating, drug-resistant bacteria, Peninsula company grabs small grant for antibiotic
    American City Business Journals

    Targeting flesh-eating, drug-resistant bacteria, Peninsula company grabs small grant for antibiotic

    It's not getting a lot of money in this effort, but the company's potential vaccine against a common, deadly bacteria could save thousands of lives.

  • PR Newswire

    Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments

    STRO-001 Initial Safety Data from an Ongoing Phase 1 Trial in Myeloma and Lymphoma presented at the European Hematology Association ("EHA") Congress, June 15, 2019 STRO-002 Phase 1 Clinical Trial ...

  • PR Newswire

    Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that its Chief Business Officer, Stephen Worsley, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 13 at 1:20 p.m. EDT in New York City. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
    Simply Wall St.

    Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Here’s What Hedge Funds Think About Sutro Biopharma, Inc. (STRO)
    Insider Monkey

    Here’s What Hedge Funds Think About Sutro Biopharma, Inc. (STRO)

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • PR Newswire

    Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair

    SOUTH SAN FRANCISCO, Calif., June 24, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Connie Matsui, retired Executive Vice President of Biogen Idec, has been appointed as Chair of Sutro's Board of Directors. In joining the Sutro Board, Ms. Matsui brings more than 35 years of innovative and principled leadership spanning the banking, biotechnology and nonprofit sectors.

  • PR Newswire

    Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

    SOUTH SAN FRANCISCO, Calif., June 18, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Steve Worsley, Chief Business Officer, will present a company overview at the JMP Securities Life Sciences Conference on Thursday, June 20 at 12:30 p.m. ET at the St. Regis Hotel in New York. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • PR Newswire

    Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

    SOUTH SAN FRANCISCO, Calif., June 15, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced encouraging interim safety data from an ongoing Phase 1 dose escalation clinical trial of its product candidate STRO-001, a novel, specific and homogeneous anti-CD74 antibody-drug conjugate (ADC), as a potential therapy for patients with B-cell malignancies. The interim data from the trial includes 21 patients and separate dosing cohorts for multiple myeloma (10 MM patients) and non-Hodgkin lymphoma (11 NHL patients), was presented at the 24th European Hematology Association (EHA) Congress in Amsterdam.

  • PR Newswire

    Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress

    SOUTH SAN FRANCISCO, Calif., May 16, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that the company will present at the upcoming European Hematology Association (EHA) Congress being held June 13-16, 2019, in Amsterdam. The abstract summarizes preliminary results from the first 14 patients enrolled in the company's ongoing Phase 1 study of STRO-001, the first antibody-drug conjugate generated with Sutro's novel cell-free protein synthesis technology, in patients with advanced B-cell malignancies.

  • PR Newswire

    Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments

    STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association ("EHA") Congress, June 15, 2019 STRO-002 Phase 1 Clinical ...

  • How free-flowing cash is accelerating small companies' cancer drug trials
    American City Business Journals

    How free-flowing cash is accelerating small companies' cancer drug trials

    An unprecedented biotech investment boom means smaller companies can accelerate early-stage drug trials and, potentially, carry them to more patients faster.

  • PR Newswire

    Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., April 4, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central Hotel in New York. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

  • PR Newswire

    Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

    STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO, Calif. ...

  • PR Newswire

    Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

    SOUTH SAN FRANCISCO, Calif., March 15, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that it has dosed the first patient in a Phase I study of STRO-002, an anti-folate receptor alpha (FoIRα) antibody-drug conjugate (ADC), in patients with ovarian and endometrial cancers. This is the second product candidate to be evaluated in clinical trials resulting from Sutro's XpressCF+™ technology platform.

  • PR Newswire

    Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., March 5, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott Copley Place in Boston. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • PR Newswire

    Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry

    SOUTH SAN FRANCISCO, Calif., Jan. 29, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced the appointment of Andreas Maderna, Ph.D., as vice president of chemistry. Dr. Maderna has extensive experience building successful scientific teams and a strong background in medicinal chemistry. "Dr. Maderna arrives at an important time for the company as we continue to fortify our leadership team and advance our cancer therapy pipeline," said Sutro CEO Bill Newell.

  • PR Newswire

    Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 3, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 10, 2019 at 11:30 a.m. PT / 2:30 p.m. ET at the Westin St. Francis Hotel in San Francisco. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

  • DAFNA Capital Management Return, AUM and Holdings
    Insider Monkey

    DAFNA Capital Management Return, AUM and Holdings

    DAFNA Capital Management, LLC is a Los Angeles-based hedge fund launched by Dr. Nathan Fischel, back in 1999. Dr. Fischel is an experienced Pediatric Hematologist-Oncologist, who graduated from the Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. For his post-graduate studies […]

  • PR Newswire

    Sutro Achieves $10 Million Milestone Payment from Celgene

    SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), today announced that the company earned $10 million in a milestone payment from Celgene triggered by the successful development of a dry powder XtractCFTM formulation, using spray drying technology, which is well established in the pharmaceutical industry. Dried XtractCFTM is a significant advancement, facilitating the commercial-scale manufacturing of protein therapeutics, using Sutro's proprietary cell-free XpressCFTM technology for its fully owned and partnered programs.

  • This year's Bay Area IPO batch remains up 44% despite market turbulence
    American City Business Journals

    This year's Bay Area IPO batch remains up 44% despite market turbulence

    Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.

  • PR Newswire

    Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics will present at the 30th Annual Piper Jaffray Healthcare Conference.

  • PR Newswire

    Sutro Biopharma Reports Third Quarter 2018 Financial Results

    -- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN FRANCISCO, Calif. ...

  • PR Newswire

    Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

    - Initiation of Phase 1 Trial Planned for Early 2019 - Company's Second Cell-Free ADC Addressing Unmet Medical Need in Oncology SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2018 /PRNewswire/ -- Sutro Biopharma, ...

  • PR Newswire

    Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors

    SAN FRANCISCO, Nov. 8, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), today announced that Shalini Sharp, Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., has been appointed to Sutro's Board of Directors. As a new member of Sutro's board, Ms. Sharp brings over 20 years of experience in the life sciences industry covering strategic financial planning, corporate and business development, risk analysis and investor relations. Ms. Sharp has been Chief Financial Officer at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on rare genetic disease treatments since 2012, where she leads the company's corporate finance, information technology, and strategy functions.